Purdue Pharma Announces Risk Strategy for ButransTM

Working with the Food and Drug Administration (FDA), Purdue Pharma L.P. has announced the development of a Risk Evaluation and Mitigation Strategy (REMS) for Butrans(tm) (buprenorphine) Transdermal System.   

The goals of the Butrans REMS Program are:

  1. To inform patients and healthcare professionals about the potential for abuse, misuse, and overdose from, and addiction to Butrans; and
  2. To inform patients and healthcare professionals about the safe use of Butrans

For more idetails visit www.butransrems.com<http://www.butransrems.com> which provides important information for healthcare professionals as well as patients and caregivers.

Printer-Friendly Version


2014 OOA
Member Census

  • FREE IT Services Checkup
  • Chance to win $100 Visa Gift Card
  • Access to other Members-only Benefits

Update Information Now

Contact Us

Call (855) 319-7828 today
to schedule a complimentary practice consultation.

An hour with our team could save you thousands of dollars!

Upcoming Events

 August 2018 
SMTWTFS
   1234
5678910
11
12
13
14
15
16
1718
19202122
232425
262728293031 
view all >>>